Santaris Pharma A/S is to receive $6.5 million upfront from Shire Plc for giving the UK company access to its locked nucleic acid (LNA) drug platform for identifying drug candidates against certain targets to treat rare genetic disorders.
Santaris Pharma A/S is to receive $6.5 million upfront from Shire Plc for giving the UK company access to its locked nucleic acid (LNA) drug platform for identifying drug candidates against certain targets to treat rare genetic disorders.